bendamustine hydrochloride has been researched along with Cytokine Release Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballard, HJ; Barta, SK; Chen, AI; Chong, EA; Garfall, A; Gerson, JN; Ghilardi, G; Gier, S; Hodges Dwinal, A; Jäger, U; Landsburg, JD; Maziarz, RT; Myers, J; Napier, E; Nasta, SD; Pajarillo, R; Porter, DL; Ruella, M; Schachter, L; Schuster, SJ; Svoboda, J; Victoriano, D; Weber, E; Williamson, S; Wohlfarth, P; Yelton, R | 1 |
1 other study(ies) available for bendamustine hydrochloride and Cytokine Release Syndrome
| Article | Year |
|---|---|
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.
Topics: Bendamustine Hydrochloride; Cyclophosphamide; Cytokine Release Syndrome; Humans; Immunotherapy, Adoptive; Lymphocyte Depletion; Lymphoma, Large B-Cell, Diffuse; Receptors, Antigen, T-Cell | 2022 |